AXSM
Axsome Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2015-11-19
$139.61
+3.60 (+2.65%)
last quote
Want the full multi-source brief on AXSM?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$139.61
High
$145.50
Low
$136.88
Previous close
$136.01
Fundamentals
Market cap
$7.51B
P/E (TTM)
—
P/S (TTM)
9.68x
P/B
71.94x
Gross margin
93.24%
Operating margin
-23.96%
Net margin
-24.68%
Rev growth (YoY)
56.87%
EPS growth (YoY)
—
ROE
-255.60%
52W high
$260.19
52W low
$123.00
Beta
0.85x
Industry peers
by market cap
Recent SEC filings
CIK 1579428filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 17h
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
BofA said concerns about adoption of Axsome’s Alzheimer’s agitation treatment and its ability to meet full-year 2027 revenue estimates have weighed on shares.
Yahoo · 19h
Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says
Axsome Therapeutics (AXSM) could achieve earnings in 2027, backed by its recent financials and growi
Yahoo · 23h
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation ConferenceFireside Chat: Monday, November 9, 2026, at 11:30 a.m
Benzinga · 1d
Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.
Yahoo · 1d
Revenue Growth And Narrower Losses Could Change The Case For Axsome Therapeutics Stock
Axsome Therapeutics reported third quarter 2026 revenue of US$259.69 million and a net loss of US$12.88 million, with basic and diluted loss per share of US$0.25, compared with the same period a year earlier. The nine month figures show revenue of US$669.27 million and a net loss of US$128.73 million, which gives investors a fuller view of Axsome Therapeutics’ scale, spending and loss profile beyo
Yahoo · 1d
Axsome Therapeutics Inc (AXSM) (Q3 2026) Earnings Call Highlights: Revenue Tops $1 Billion Run ...
Axsome Therapeutics Inc (AXSM) posted $259.7 million in Q3 2026 revenue, up 52% year-over-year, while narrowing its net loss to $12.9 million and advancing a 10-program pipeline toward key catalysts.
Yahoo · 1d
AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
Axsome reported total net product revenue of $259.7 million, up 52% from $171.0 million a year earlier, with Auvelity accounting for a majority of it.
Yahoo · 1d
Earnings Calendar and Analysis for This Week (June 8-12)
Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial